King Luther Capital Management Corp Buys 5,761 Shares of Eli Lilly and Company $LLY

Key Points

• King Luther Capital Management increased its Eli Lilly stake by 3.1% in the fourth quarter, adding 5,761 shares to reach 191,416 shares valued at about $205.7 million.
• Institutional interest remains strong, with hedge funds and other investors making sizable changes to their holdings; institutions now own about 82.53% of Eli Lilly’s stock.
• Eli Lilly continues to draw bullish analyst sentiment, with a consensus rating of Moderate Buy and an average price target of $1,227, while the company recently beat earnings and revenue expectations.

King Luther Capital Management Corp grew its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 3.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 191,416 shares of the company's stock after purchasing an additional 5,761 shares during the quarter. Eli Lilly and Company makes up approximately 0.8% of King Luther Capital Management Corp's portfolio, making the stock its 27th biggest position. King Luther Capital Management Corp's holdings in Eli Lilly and Company were worth $205,711,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. ICW Investment Advisors LLC increased its stake in shares of Eli Lilly and Company by 459.1% in the fourth quarter. ICW Investment Advisors LLC now owns 5,652 shares of the company's stock worth $6,074,000 after buying an additional 4,641 shares during the period. Expressive Wealth LLC purchased a new stake in Eli Lilly and Company during the 4th quarter valued at $721,000. Steel Grove Capital Advisors LLC boosted its position in Eli Lilly and Company by 103.1% during the 4th quarter. Steel Grove Capital Advisors LLC now owns 604 shares of the company's stock valued at $649,000 after buying an additional 19,986 shares during the period. TrustBank bought a new stake in Eli Lilly and Company in the 4th quarter worth $2,731,000. Finally, Roundview Capital LLC grew its holdings in Eli Lilly and Company by 14.9% in the 4th quarter. Roundview Capital LLC now owns 7,199 shares of the company's stock worth $7,737,000 after acquiring an additional 935 shares during the last quarter. Institutional investors own 82.53% of the company's stock.

Wall Street Analyst Weigh In

LLY has been the subject of several recent analyst reports. Berenberg Bank upped their price objective on shares of Eli Lilly and Company from $950.00 to $1,050.00 and gave the company a "hold" rating in a research note on Thursday, February 19th. UBS Group reissued a "buy" rating on shares of Eli Lilly and Company in a research note on Wednesday, March 18th. Bank of America boosted their price target on Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the company a "buy" rating in a report on Tuesday. Argus upped their price target on Eli Lilly and Company from $930.00 to $1,200.00 and gave the company a "buy" rating in a research report on Monday, February 9th. Finally, TD Cowen increased their price objective on Eli Lilly and Company from $960.00 to $1,250.00 and gave the stock a "buy" rating in a report on Thursday, January 29th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $1,227.00.

Eli Lilly and Company Stock Up 0.2%

Shares of NYSE LLY opened at $1,066.77 on Wednesday. The firm has a fifty day simple moving average of $946.28 and a two-hundred day simple moving average of $1,006.64. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,133.95. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. The firm has a market capitalization of $1.00 trillion, a PE ratio of 37.90, a price-to-earnings-growth ratio of 1.16 and a beta of 0.48.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating analysts' consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. During the same quarter in the previous year, the firm posted $3.34 EPS. The company's revenue for the quarter was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities analysts expect that Eli Lilly and Company will post 35.82 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, May 15th. Eli Lilly and Company's payout ratio is presently 24.58%.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly announced it will acquire three vaccine developers — Curevo, LimmaTech Biologics, and Vaccine Company — in deals worth up to about $3.8 billion, expanding its infectious-disease and vaccine portfolio beyond diabetes and obesity. Lilly announces three acquisitions to build infectious disease portfolio
• Positive Sentiment: Investors also reacted to strong news from Lilly’s experimental gene therapy VERVE-102, which cut LDL cholesterol and PCSK9 sharply in early trial data, reinforcing optimism around the company’s broader growth pipeline. VERVE-102 trial results
• Positive Sentiment: Analysts and media coverage continued to highlight Lilly as a long-term winner in obesity and pharma, supported by persistent demand for its weight-loss drugs and upbeat commentary on its growth prospects. Motley Fool article on undervaluation
• Neutral Sentiment: Broader market gains and hopes for a diplomatic resolution between the U.S. and Iran helped lift equities overall, providing a supportive backdrop for Lilly alongside the company-specific headlines. Market wrap article
• Neutral Sentiment: Some healthcare-sector weakness on the day may have partially offset the company-specific optimism, but it does not appear to be the main driver for LLY. Healthcare sector decline article

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.